Smart Retinal Implants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The smart retinal implants market size is expected to grow from USD 24.40 million in 2025 to USD 27.67 million in 2026 and is forecast to reach USD 51.89 million by 2031 at 13.40% CAGR over 2026-2031. This report is Segmented by Product Type (Epiretinal, Subretinal, and More), Platform (Wired Systems, and More), Component (Array, Camera, and More), Material (Implant Array, and More), Disease (Retinitis Pigmentosa, and More), End User (Hospitals, Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Smart Retinal Implants Market Trends and Insights

Rising Clinical Validation for Vision Restoration

The PRIMAvera study has significantly strengthened the clinical foundation of the smart retinal implants market. Published in October 2025, the trial demonstrated that 80% of patients with geographic atrophy achieved meaningful visual acuity improvements after 12 months. This shift enables evaluations based on real patient outcomes rather than engineering potential. Furthermore, these results have advanced discussions from feasibility to approval and market readiness in Europe, where Science Corporation submitted its CE Mark application in 2025. The market is also gaining validation across multiple technical paths, as Cortigent's 6-year Orion feasibility data from January 2026 showed less than 4% electrode loss and improved visual function in all 6 subjects. This diversification of clinical evidence has increased confidence among surgeons, regulators, and investors.

Expanding Addressable Population With Geographic Atrophy and Retinitis Pigmentosa

The smart retinal implants market benefits from a large patient base, particularly in geographic atrophy and retinitis pigmentosa, where durable vision restoration options remain limited. Geographic atrophy affects millions globally, while retinitis pigmentosa impacts an additional 1.5 to 2 million people, ensuring sustained demand even with a gradual commercial rollout. The PRIMA platform has expanded its focus through a new clinical study targeting patients with photoreceptor degeneration, including retinitis pigmentosa and Stargardt-related vision loss. Japan's STS Phase 3 program, launched in September 2025, highlights growing institutional support for retinal implant development in Asia, which is critical for future market expansion. While optogenetics is advancing in retinitis pigmentosa, the diverse clinical needs across disease stages and retinal structures ensure continued demand for implants.

Limited Visual Acuity Gains Versus Surgical and Device Complexity

The smart retinal implants market has achieved significant clinical advancements, but a gap remains between these improvements and their application in daily visual functions. The PRIMAvera study demonstrated progress in visual acuity; however, many patients still could not achieve independence in tasks like reading, face recognition, or navigation. The trial reported 26 serious adverse events among 38 participants, with 95% resolving within two months, highlighting challenges in broader adoption. Additionally, the implantation process requires specialized vitreoretinal or neurosurgical expertise, which is not widely available, slowing the transition from clinical trials to routine care.

Other drivers and restraints analyzed in the detailed report include:

• Convergence of Miniaturized Electronics and Wireless Power Transfer
• Precision-Targeted Retinal Stimulation and AI-Assisted Scene Encoding
• High Procedure Cost and Unclear Reimbursement Pathways

Segment Analysis

In 2025, subretinal implants captured 54.66% of the smart retinal implants market, solidifying their top position. Their advantage lies in their placement beneath the retina, enabling direct stimulation of intact bipolar cells and offering superior visual fidelity compared to many surface-mounted designs. The PRIMA system stands out in this segment, with its October 2025 publication bolstering subretinal technology's clinical credibility. As a result, the market views subretinal systems as the most promising avenue for treating patients with geographic atrophy and related degenerations.

While epiretinal systems played a pivotal role in the field's early clinical history, they no longer steer the course of new developments. Suprachoroidal implants are gaining traction as a less risky surgical alternative, with a second-generation 44-channel device boasting 97% electrode functionality after 2.7 years, as reported in a 2025 feasibility study. Meanwhile, cortical visual prostheses are on a rapid ascent, projected to grow at a 14.20% CAGR through 2031. Their broader appeal stems from their ability to cater to patients unsuitable for retinal implants, including those with optic nerve damage or advanced retinal diseases.

In 2025, wired systems commanded 61.53% of the revenue, a testament to the enduring influence of earlier implant programs and design choices. However, this dominance is more historical than strategic. Most recent advancements in the smart retinal implants market have pivoted towards wireless and hybrid systems. While wired architectures offer familiar engineering pathways and stable transmission, their reliance on cables and external hardware complicates surgery, patient comfort, and MRI compatibility over time. Consequently, while the wired base remains relevant in the near term, it isn't setting the pace for future designs.

Wireless systems are on a trajectory to grow at a 15.15% CAGR through 2031, marking them as the fastest-growing platform in the smart retinal implants arena. The PRIMA system exemplifies this trend, utilizing near-infrared light for power and data transmission, thereby eliminating the need for a transcutaneous cable. This innovation significantly enhances both patient experience and surgical ease. Furthermore, a 2026 technical study highlighted the potential of photovoltaic arrays to downsize pixels without compromising wireless functionality, bolstering the platform's long-term prospects.

Complete Report Scope:

• By Product Type
  • Epiretinal Implants
  • Subretinal Implants
  • Suprachoroidal Implants
  • Cortical Visual Prostheses
• By Implant Platform
  • Wired Systems
  • Wireless Systems
  • Hybrid Systems
• By Component
  • Implant Array
  • External Glasses and Camera System
  • Processing Unit
  • Power Transmission Module
  • Surgical Accessories and Tools
• By Material
  • Biocompatible Metals (Platinum, Titanium)
  • Polymers (Polyimide, Silicone)
  • Ceramics
  • Nanomaterials (Graphene, Carbon Nanotubes)
  • Hybrid Materials
• By Disease Indication
  • Retinitis Pigmentosa
  • Geographic Atrophy Due to Age-Related Macular Degeneration
  • Other Degenerative Retinal Disorders
• By End User
  • Hospitals and Ophthalmic Surgery Centers
  • Specialty Eye Clinics
  • Academic and Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America dominated the smart retinal implants market, holding a 40.65% share. The United States led this growth due to its strong specialist capacity and supportive regulatory pathways, which advanced both retinal and cortical device programs. Science Corporation progressed its PRIMA program through U.S. regulatory channels in 2025, while Cortigent presented 6-year study data for its Orion program under Breakthrough Device status in January 2026. The region's concentrated network of implanting hospitals, device developers, and ophthalmic research centers further supports clinical enrollment and commercial readiness.

Europe remains the second-largest hub in the smart retinal implants market. The region played a key role in the PRIMAvera program, with an October 2025 publication strengthening the evidence package for European regulators and advancing the CE Mark review. Germany, France, and the UK stand out for their combination of specialist retinal surgery and academic trial participation. Europe is also a critical launch region, as successful approval could establish a structured commercial pathway, despite slower reimbursement timelines.

Asia-Pacific is projected to grow at a 15.44% CAGR through 2031, making it the fastest-growing region in the smart retinal implants market. Japan drives this growth with its aging population and advancements in suprachoroidal systems and wide-field chiplet implants. Osaka University initiated its STS Phase 3 trial in September 2025, while Tohoku University is advancing a government-backed 3D laminated artificial retina targeting a 160-degree visual field. The region also benefits from Australia's suprachoroidal prosthesis program, expanding its innovation base. South America and the Middle East and Africa currently contribute less revenue but are expected to grow as retinal disease prevalence rises and ophthalmic infrastructure improves.

List of Companies Covered in this Report:

• Bionic Vision Technologies Pty Ltd
• Boston Scientific
• GenSight Biologics SA
• iBionics Inc.
• Intelligent Implants GmbH
• LambdaVision, Inc.
• Nano Retina Ltd.
• Nidek
• Ocumetics Technology Corporation
• Ophthorobotics AG
• Optobionics Corporation
• Pixium Vision SA
• Retina Implant AG
• Science Corporation
• Second Sight Medical Products
• VisionCare Ophthalmic Technologies, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support